Introduction and Methodology: <i>Standards of Care in Diabetes—2024</i>Nuha A. ElSayed, Robert A. Gabbay, Grazia Aleppo et al.|Diabetes Care|2023Cited by 184
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F.E. Mann, Katherine R. Tuttle, Peter Rossing et al.|Nature Medicine|2024Cited by 152
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E. Pratley, Kenneth W. Mahaffey, Katherine R. Tuttle et al.|Journal of the American College of Cardiology|2024Cited by 107
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysisJohannes F.E. Mann, Vlado Perkovic, John B. Buse et al.|Diabetes Obesity and Metabolism|2021Cited by 105
Relation of the White Blood Cell Count to Obesity and Insulin Resistance: Effect of Race and GenderRichard E. Pratley, Clifton Bogardus, Charlton Wilson|Obesity Research|1995Cited by 80